在正常和病理条件下,vemurafenib作为RIPK1抗剂抑制了亡
1State Key Laboratory of Systems Medicine for Cancer, Center for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
一种抗癌药物Vemurafenib通过阻断RIPK1激酶活性,有效地抑制亡. 这一发现为由编程细胞死亡驱动的炎症性疾病提供了新的治疗潜力.
科学领域:
- 分子生物学分子生物学
- 细胞生物学 细胞生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 亡,一个被编程的细胞死亡途径,显著促进炎症性疾病.
- 向亡提供治疗前景,但有效的抑制剂是有限的.
- 受体相互作用蛋白激酶1 (RIPK1) 是死的关键调节者.
研究的目的:
- 为了确定新型的死细胞灭亡抑制剂.
- 评估FDA批准的抗癌药物Vemurafenib作为死抑制剂.
- 为了阐明Vemurafenib对RIPK1和亡的作用机制.
主要方法:
- 药物查和鉴定vemurafenib作为一个死亡灭抑制剂.
- 生物化学测试以评估RIPK1激酶活性抑制.
- 细胞检测评估体复合体的形成和亡.
- 在体内研究,使用亡相关疾病的动物模型.
主要成果:
- 韦穆拉芬尼直接与RIPK1结合,抑制其激酶活性和下游信号传递.
- 维穆拉芬尼防止了体复合体的组合,从而阻断了亡.
- 韦穆拉菲尼布通过独特的全结合部位稳定了RIPK1在非活性构造中.
- 用Vemurafenib进行预治疗表明,体内对与亡相关的疾病有显著的保护.
结论:
- 韦穆拉芬尼作为一种强大的RIPK1抗剂,有效地抑制亡.
- 这些发现提供了强有力的临床前证据,支持在与亡相关的炎症性疾病中重新使用Vemurafenib.
- 维穆拉菲尼布代表了治疗涉及失调亡的条件的有希望的治疗候选者.
更多相关视频
09:15Tyramide Signal Amplification for the Immunofluorescent Staining of ZBP1-Dependent Phosphorylation of RIPK3 and MLKL After HSV-1 Infection in Human Cells
Published on: October 20, 2022
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
相关概念视频
Necrosis
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Inhibition of Cdk Activity
Abnormal Proliferation
The Intrinsic Apoptotic Pathway
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
MAPK Signaling Cascades
